191 related articles for article (PubMed ID: 27873026)
1. Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis.
Tao X; Wang W; Jing F; Wang Z; Chen Y; Wei D; Huang X
Neurol Sci; 2017 Feb; 38(2):325-330. PubMed ID: 27873026
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
3. Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis.
Chen D; Hou S; Zhao M; Sun X; Zhang H; Yang L
Eur J Neurol; 2018 Aug; 25(8):1049-e80. PubMed ID: 29611886
[TBL] [Abstract][Full Text] [Related]
4. Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Gamez J; Armengol M
Curr Med Res Opin; 2006 May; 22(5):885-95. PubMed ID: 16709310
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH; Shin HY; Kim SM
Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
[TBL] [Abstract][Full Text] [Related]
6. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).
Konishi T; Yoshiyama Y; Takamori M; Saida T
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):448-50. PubMed ID: 15716549
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic efficacy and safety of tacrolimus for intractable myasthenia gravis: a report of 36 patients].
Feng HY; Liu WB; Qiu L; Huang X; Huang RX
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(45):3190-2. PubMed ID: 22333101
[TBL] [Abstract][Full Text] [Related]
9. Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients.
Meng HY; Li X; Jin WL; Yan CK; Dong XH; Xu Q; Peng YY; Li ZB; Li Y; Luo ZH; Xu LQ; Yang H
Eur J Clin Pharmacol; 2020 May; 76(5):659-671. PubMed ID: 31955224
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Cervera C; Armengol M
Neurology; 2005 May; 64(9):1641-3. PubMed ID: 15883336
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis.
Tada M; Shimohata T; Tada M; Oyake M; Igarashi S; Onodera O; Naruse S; Tanaka K; Tsuji S; Nishizawa M
J Neurol Sci; 2006 Aug; 247(1):17-20. PubMed ID: 16631797
[TBL] [Abstract][Full Text] [Related]
14. Adequate tacrolimus concentration for myasthenia gravis treatment.
Kanai T; Uzawa A; Kawaguchi N; Himuro K; Oda F; Ozawa Y; Kuwabara S
Eur J Neurol; 2017 Feb; 24(2):270-275. PubMed ID: 28102047
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
Wang L; Zhang S; Xi J; Li W; Zhou L; Lu J; Lu J; Zhang T; Zhao C
J Neurol; 2017 Nov; 264(11):2191-2200. PubMed ID: 28921038
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus.
Nagaishi A; Yukitake M; Kuroda Y
Intern Med; 2008; 47(8):731-6. PubMed ID: 18421189
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients.
Fan Z; Zheng D; Wen X; Shen F; Lei L; Su S; Zhang S; Liu Q; Zhang X; Lu Y; Di L; Shen XM; Da Y
J Neuroimmunol; 2021 Jun; 355():577571. PubMed ID: 33866281
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis.
Furukawa Y; Yoshikawa H; Iwasa K; Yamada M
J Neuroimmunol; 2008 Mar; 195(1-2):108-15. PubMed ID: 18262659
[TBL] [Abstract][Full Text] [Related]
19. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
Ponseti JM; Azem J; Fort JM; Codina A; Montoro JB; Armengol M
Clin Neurol Neurosurg; 2005 Apr; 107(3):187-90. PubMed ID: 15823673
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis.
Itani K; Nakamura M; Wate R; Kaneko S; Fujita K; Iida S; Morise S; Murakami A; Kunieda T; Takenouchi N; Yakushiji Y; Kusaka H
Neuromuscul Disord; 2021 Jun; 31(6):512-518. PubMed ID: 33903022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
